Xiaohua Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xiaohua Yang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Cailin Chen
Department of Gastroenterology, Jiangsu Shengze Hospital
2 shared publications- Chuanwu Zhu
Department of Infectious Diseases, The Affiliated Infectious Diseases Hospital, Suzhou Medical College of Soochow University, The Fifth People’s Hospital of Suzhou, China
2 shared publications - Jin Li
Department of Infectious Diseases, The Affiliated Infectious Diseases Hospital of Soochow University
2 shared publications Junchi Xu
Department of Infectious Diseases, The Affiliated Infectious Diseases Hospital of Soochow University
2 shared publications- Li Zhu
Department of Infectious Diseases, The Affiliated Infectious Diseases Hospital, Suzhou Medical College of Soochow University, The Fifth People’s Hospital of Suzhou, China
2 shared publications Mengkui Han
Department of Infectious Diseases, The Affiliated Infectious Diseases Hospital of Soochow University
2 shared publications
Latest Publications
- Open Access
- 16 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1784456
Correction: Identification of serum MicroRNAs associated with hepatic immunoinflammatory injury in chronic hepatitis B: implications for non-invasive diagnosis
- 16 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1784456
Open AccessCorrection: Identification of serum MicroRNAs associated with hepatic immunoinflammatory injury in chronic hepatitis B: implications for non-invasive diagnosis
- Open Access
- 11 December 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1671149
Identification of serum MicroRNAs associated with hepatic immunoinflammatory injury in chronic hepatitis B: implications for non-invasive diagnosis
Background and aims: Hepatitis B virus (HBV) causes chronic hepatic infection, leading to various advanced liver diseases. Currently, there is still a lack of effective non-invasive biomarkers for evaluating hepatic inflammation and fibrosis. Circulating microRNAs (miRNAs) serve as key regulators and potential biomarkers in the progression and pathogenesis of HBV-associated progressive liver diseases. Here, we characterized the miRNA profile in chronic hepatitis B (CHB) patients and probed their association with liver inflammation and fibrosis. Approaches and results: We profiled 34 candidate miRNAs in serum from a well-characterized HBV Disease Continuum Cohort, comprising 165 individuals in the discovery set (42 healthy controls, HC; 40 CHB; 42 cirrhosis; 41 hepatocellular carcinomas, HCC) and 143 in an independent testing set. Serum miRNA levels were quantified by qRT-PCR. Supervised clustering and correlation analyses revealed distinct miRNA expression profiles across disease stages. Statistical analyses included logistic regression, and ROC/AUC evaluation with 5-fold cross-validation and external validation. Unsupervised clustering and correlation with histological G/S staging revealed stage-specific miRNA signatures: miR-224-5p, miR-125a-5p, and miR-15a-5p peaked in cirrhosis and strongly correlated with fibrosis stage (miR-224-5p: r = 0.606, p = 1.5E-12), while miR-200a-3p and miR-939-5p were predominantly upregulated in HCC. Critically, miR-224-5p emerged as a robust non-invasive biomarker for cirrhosis, with exceptional diagnostic accuracy (AUC = 0.973 in discovery; 0.906 in external validation), significantly outperforming APRI (0.803) and FIB-4 (0.809), and remained the sole independent predictor in multivariable analysis (p = 0.009). For HCC detection, the miR-200a-3p/AFP combined model achieved outstanding performance (AUC > 0.9), substantially improving upon AFP alone (0.737). Bioinformatic prediction of targets (297 for miR-224-5p; 616 for miR-200a-3p) highlighted associated in cancer- and senescence-related pathways; however, these associations are in silico and require experimental validation. Conclusion: We identify miR-224-5p as a fibroinflammatory activity indicator for early cirrhosis detection and miR-200a-3p as a synergistic enhancer of AFP for non-invasive HCC diagnosis, establishing a dual miRNA signature that spans the HBV disease continuum and addresses critical gaps in current risk stratification. These findings highlight the potential of specific serum miRNAs as non-invasive biomarkers for monitoring disease progression and improving the differential diagnosis during the process of HBV-related liver diseases.
- 11 December 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1671149
Open AccessIdentification of serum MicroRNAs associated with hepatic immunoinflammatory injury in chronic hepatitis B: implications for non-invasive diagnosis
Background and aims: Hepatitis B virus (HBV) causes chronic hepatic infection, leading to various advanced liver diseases. Currently, there is still a lack of effective non-invasive biomarkers for evaluating hepatic inflammation and fibrosis. Circulating microRNAs (miRNAs) serve as key regulators and potential biomarkers in the progression and pathogenesis of HBV-associated progressive liver diseases. Here, we characterized the miRNA profile in chronic hepatitis B (CHB) patients and probed their association with liver inflammation and fibrosis. Approaches and results: We profiled 34 candidate miRNAs in serum from a well-characterized HBV Disease Continuum Cohort, comprising 165 individuals in the discovery set (42 healthy controls, HC; 40 CHB; 42 cirrhosis; 41 hepatocellular carcinomas, HCC) and 143 in an independent testing set. Serum miRNA levels were quantified by qRT-PCR. Supervised clustering and correlation analyses revealed distinct miRNA expression profiles across disease stages. Statistical analyses included logistic regression, and ROC/AUC evaluation with 5-fold cross-validation and external validation. Unsupervised clustering and correlation with histological G/S staging revealed stage-specific miRNA signatures: miR-224-5p, miR-125a-5p, and miR-15a-5p peaked in cirrhosis and strongly correlated with fibrosis stage (miR-224-5p: r = 0.606, p = 1.5E-12), while miR-200a-3p and miR-939-5p were predominantly upregulated in HCC. Critically, miR-224-5p emerged as a robust non-invasive biomarker for cirrhosis, with exceptional diagnostic accuracy (AUC = 0.973 in discovery; 0.906 in external validation), significantly outperforming APRI (0.803) and FIB-4 (0.809), and remained the sole independent predictor in multivariable analysis (p = 0.009). For HCC detection, the miR-200a-3p/AFP combined model achieved outstanding performance (AUC > 0.9), substantially improving upon AFP alone (0.737). Bioinformatic prediction of targets (297 for miR-224-5p; 616 for miR-200a-3p) highlighted associated in cancer- and senescence-related pathways; however, these associations are in silico and require experimental validation. Conclusion: We identify miR-224-5p as a fibroinflammatory activity indicator for early cirrhosis detection and miR-200a-3p as a synergistic enhancer of AFP for non-invasive HCC diagnosis, establishing a dual miRNA signature that spans the HBV disease continuum and addresses critical gaps in current risk stratification. These findings highlight the potential of specific serum miRNAs as non-invasive biomarkers for monitoring disease progression and improving the differential diagnosis during the process of HBV-related liver diseases.
- 1 October 2019
- Published by Elsevier in Archives of Medical Research
- Vol. 50 (7) , 413-422
β-arrestin2 Inhibits Apoptosis and Liver Inflamation Induced by Ischemia-reperfusion in Mice via AKT and TLR4 Pathway
- 1 October 2019
- Published by Elsevier in Archives of Medical Research
- Vol. 50 (7) , 413-422
β-arrestin2 Inhibits Apoptosis and Liver Inflamation Induced by Ischemia-reperfusion in Mice via AKT and TLR4 Pathway